Azetidine derivative

Цитирование НПИ

Dorsey, et al; Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer; J. Med. Chem. (2008); 51; 1068-1072.
Dou, Q.P. et al; Overview of Proteasome Inhibitor-Based Anti-Cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors Versus Future Generation Inhibitors of Ubiquitin-Proteasome System; Current Cancer Drug Targets; 14(6), Dec. 31, 2014, pp. 517-536.
European Patent Office; Communication—Supplementary European Search Report; EP Appl. No. 18760796.5; dated Nov. 11, 2020; (6 pgs.).
Ruggeri, B., et al; The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer; Advances in Pharmacology (San Diego, CA, US); vol. 57, Dec. 31, 2009; pp. 91-135.
State Intellectual Property Office of the P.R. China; International Search Report of International Application No. PCT/CN2018/077583, dated Jun. 1, 2018.
Получить PDF